Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.92 - $1.44 $251,385 - $393,472
-273,245 Reduced 62.12%
166,656 $206,000
Q4 2023

Feb 14, 2024

SELL
$0.64 - $6.49 $13,063 - $132,473
-20,412 Reduced 4.43%
439,901 $461,000
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $1.7 Million - $2.83 Million
258,896 Added 128.54%
460,313 $3.15 Million
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $95,910 - $129,339
12,156 Added 6.42%
201,417 $2.09 Million
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $87,215 - $221,431
-12,336 Reduced 6.12%
189,261 $1.53 Million
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $284,120 - $364,221
-19,827 Reduced 8.95%
201,597 $3.18 Million
Q3 2022

Nov 14, 2022

SELL
$13.07 - $18.22 $382,820 - $533,663
-29,290 Reduced 11.68%
221,424 $3.49 Million
Q2 2022

Aug 15, 2022

SELL
$10.16 - $17.08 $678,952 - $1.14 Million
-66,826 Reduced 21.04%
250,714 $3.5 Million
Q1 2022

May 16, 2022

BUY
$9.74 - $17.92 $149,840 - $275,681
15,384 Added 5.09%
317,540 $5.12 Million
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.49 $368,909 - $555,920
30,066 Added 11.05%
302,156 $4.39 Million
Q3 2021

Nov 12, 2021

BUY
$13.38 - $18.8 $1.18 Million - $1.66 Million
88,303 Added 48.05%
272,090 $4.94 Million
Q2 2021

Aug 16, 2021

BUY
$17.08 - $29.6 $3.14 Million - $5.44 Million
183,787 New
183,787 $3.23 Million
Q2 2020

Aug 14, 2020

SELL
$1.04 - $1.73 $114,400 - $190,300
-110,000 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$0.75 - $2.18 $6,636 - $19,290
8,849 Added 8.75%
110,000 $114,000
Q4 2019

Feb 14, 2020

SELL
$1.02 - $1.97 $14,572 - $28,145
-14,287 Reduced 12.38%
101,151 $191,000
Q3 2019

Nov 14, 2019

SELL
$0.79 - $2.47 $9,892 - $30,929
-12,522 Reduced 9.79%
115,438 $125,000
Q2 2019

Aug 15, 2019

BUY
$2.13 - $7.06 $272,554 - $903,397
127,960 New
127,960 $280,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.